JUPITER NEUROSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Apr 1, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 1, 2026
JUNS$2.22+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash | $3,789,342 | $3,769,510 |
| Account receivable | 2,637 | - |
| Prepaid contracts | 766,667 | 766,667 |
| Inventory, net | 159,790 | - |
| Other current assets | 106,542 | 114,086 |
| Total current assets | 4,824,978 | 4,650,263 |
| Operating lease right of use asset, net | 23,214 | 69,642 |
| Prepaid contracts, noncurrent | 712,055 | 1,478,721 |
| Other assets | 3,783 | 3,783 |
| Total assets | $5,564,030 | $6,202,409 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable and accrued expenses | $638,646 | $396,483 |
| Accrued compensation | 1,397,357 | 1,415,093 |
| Accrued interest | 39,829 | 1,064 |
| Deferred revenue | 735 | - |
| Current portion of operating lease liability | 21,247 | 50,082 |
| Note payable, related party | - | 146,432 |
| Convertible notes payable, fair value | 5,298,068 | - |
| Other liability | - | - |
| Total current liabilities | 7,395,882 | 2,009,154 |
| Operating lease liability, net of current portion | - | 21,247 |
| Total liabilities | 7,395,882 | 2,030,401 |
| Commitments and Contingencies (Note 8) | - | - |
| Stockholders’ Deficit: | ||
| Series A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding | - | - |
| Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively | 3,444 | 3,310 |
| Additional paid in capital | 32,831,730 | 30,190,827 |
| Accumulated deficit | (34,667,026) | (26,022,129) |
| Total stockholders’ deficit | (1,831,852) | 4,172,008 |
| Total liabilities and stockholders’ deficit | $5,564,030 | $6,202,409 |
The accompanying notes are an integral part of these audited financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.